This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
H.C. Wainwright notes that Roche’s (RHHBY) persevERA trial “disappointingly” failed, though the firm does not view the frontline opportunity as eliminated for palazestrant and does not believe the persevERA trial is “a complete readthrough” to Olema Oncology’s (OLMA) OPERA-02 trial, which is evaluating palazestrant plus ribociclib. Differences in combo agents could favor OPERA-02, argues the analyst, who keeps a Buy rating on Olema shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
Disclaimer & DisclosureReport an Issue
- Olema Pharmaceuticals, Inc. (OLMA) Q4 Earnings Cheat Sheet
- Asymmetric Upside on Olema Ahead of Roche’s persevERA Readout: Buy/High Risk Maintained on Palazestrant Optionality
- Olema Oncology initiated with a Buy at Stifel
- Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
- Olema Oncology announces departure of COO, CFO Shane Kovacs
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
